Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 20/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510181 | 0.83 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL14043094 | 0.65 | — | — | |
| SCHEMBL12427881 | 0.65 | TYMP (0.43) | KCNH2 | |
| SCHEMBL943184 | 0.65 | TYMP (0.43) | KCNH2 | |
| SCHEMBL941529 | 0.65 | LMNA (0.46) | KCNH2 | |
| SCHEMBL12427963 | 0.65 | TYMP (0.43) | KCNH2 | |
| SCHEMBL22057392 | 0.64 | — | — | |
| SCHEMBL12231940 | 0.64 | — | — | |
| SCHEMBL22057390 | 0.63 | HRH4 (0.30) | — | |
| SCHEMBL13063786 | 0.62 | KMT2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | HIF1AN, HIF1A, HYOU1 | KCNH2 1049/4885 |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | HIF1AN, HIF1A, HYOU1 | KCNH2 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.